×

Research Updates & MSA Awareness

FEBRUARY & MARCH 2024

Join the #MOVE4MSA with Defeat MSA/Vaincre AMS Canada!

MSA Research Trial Updates

GREAT NEWS

– REPORTED FIRST DISEASE MODIFYING THERAPY FOR MSA!

Lundbeck Pharmaceutical announced supportive phase II results with Lu AF82422 in the treatment of Multiple System Atrophy from the AMULET trial.

To quote Lundbeck :

„Signals of efficacy were observed across clinical and biomarker endpoints in a small exploratory proof-of-concept trial of 61 Multiple System Atrophy (MSA) patients (40 on Lu AF82422 versus 21 on placebo).“

„Although the AMULET trial did not show statistical significance on its primary endpoint in slowing the rate of progression of MSA as measured by UMSARS Total Score, a trend of a slowing MSA progression was observed in the group exposed to Lu AF82422.“

 

WATCH LUNDBECK’S ANNOUNCEMENT HERE: https://getvisualtv.net/stream/?lundbeck-o3zxgjk1hd

 

WE ARE ADVOCATING FOR MSA PATIENTS EVERYWHERE, FOR MORE MONEY & ATTENTION FROM THE PHARMA SECTOR!

DONATE TO OUR RESEARCH FUND – www.defeatmsa.org/donate-to-us